CTOs on the Move


 
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.biosig.com
  • 12424 Wilshire Boulevard Suite 745
    Los Angeles, CA USA 90025
  • Phone: 310.620.9320

Executives

Name Title Contact Details
Barry Keenan
Vice President of Engineering Profile

Funding

BioSig raised $17.5M on 06/24/2020

Similar Companies

Minimax

Minimax is a West Hempstead, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avid Medical Inc

Avid Medical Inc is a Toano, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medlink Imaging

Medlink Imaging is a Teterboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meridian Medical Group

Meridian Medical Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sight Sciences

Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world`s most prevalent eye diseases. The company`s surgical glaucoma product portfolio features the OMNI Surgical System, a dually indicated MIGS device that facilitates the performance of both ab interno trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm`s canal and collector channels) with a single device and single corneal incision. The company`s non-surgical dry eye product portfolio consists of the TearCare for ophthalmologists and optometrists. TearCare is a software-controlled, wearable, therapeutic eyelid technology designed to melt and clear obstructions of the meibomian glands within the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to conform to all eyelid anatomies and achieve therapeutic meibum melting temperatures at the tarsal conjunctiva thereby clearing meibomian gland obstructions while sparing the cornea. Improved meibum production results in a higher quality lipid layer and higher quality tears.